

ISMMS SARS-CoV-2 updated policy

	VOC, VOI, and VUM strains	All other strains
in-vitro work	BSL-2+	BSL-2+
in-vivo work (work involving live animals)	ABSL-3	ABSL-3
Clinical specimens	BSL-2	
Work involving genetic manipulation of the virus	IBC must review and approve the eSafety research registration prior to initiation of research	

- Applicable from February 3rd, 2025
- NIH and CDC downgraded the regulatory status of SARS-CoV-2 (now RG-2 agent).
- IBC to conduct local risk assessments.
- Removal of stocks from BSL-3 requires metagenomic sequencing to verify the absence of cross-contamination by other agents.
- Stocks acquired from commercial sources may be directly handled with BSL-2 practices.
- Need to update eSafety and eIACUC submissions.